FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Ca A Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997;44(4):973–989.9286295
   PubMed Web of Science ®Google Scholar
• Yuan G, Chen J, Wu D, Gao C. Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: a retrospective study. Onco Targets Ther. 2017;10:2745–2750. doi:10.2147/OTT28603424
   PubMed Web of Science ®Google Scholar
• Bacci, G., Longhi, A., Versari, M., et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106(5):1154–1161. doi:10.1002/cncr.2173016421923
   PubMed Web of Science ®Google Scholar
• Simpson, S., Dunning, MD., de Brot, S., et al. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 2017;59(1):71. doi:10.1186/s13028-017-0347-329065898
   PubMedGoogle Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–1543. doi:10.1002/cncr.v115:719197972
   PubMed Web of Science ®Google Scholar
• Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol. 2013;5(Issue 1):147.23700373
   PubMedGoogle Scholar
• Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res. 1994;5(4):353. doi:10.1016/0955-2235(94)00007-87780086
   PubMedGoogle Scholar
• Powers CJ, Mcleskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7(3):165–197.11021964
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. doi:10.1126/scitranslmed.3001451
   PubMed Web of Science ®Google Scholar
• Elbauomy ES, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9(2):R23. doi:10.1186/bcr166517397528
   PubMed Web of Science ®Google Scholar
• Zhan X, Bates B, Hu XG, Goldfarb M. The human FGF-5 oncogene encodes a novel protein related to fibroblast growth factors. Mol Cel Biol. 1988;8(8):3487–3495. doi:10.1128/MCB.8.8.3487
   PubMed Web of Science ®Google Scholar
• Kornmann M, Ishiwata T, Beger HG, Korc M. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene. 1997;15(12):1417–1424. doi:10.1038/sj.onc.12013079333017
   PubMed Web of Science ®Google Scholar
• Hanada, K., Perry-Lalley, DM., Ohnmacht, GA., et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001;61(14):5511.11454700
   PubMed Web of Science ®Google Scholar
• Allerstorfer S, Sonvilla G, Fischer H, et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene. 2008;27(30):4180. doi:10.1038/onc.2008.6118362893
   PubMed Web of Science ®Google Scholar
• Zhou J, Shen B, Zhang W, et al. One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. Int J Biochem Cell Biol. 2014;46(1):49–55. doi:10.1016/j.biocel.2013.10.01024269190
   PubMedGoogle Scholar
• Tome Y, Tsuchiya H, Hayashi K, et al. In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential. J Cell Biochem. 2010;108(2):362–367. doi:10.1002/jcb.v108:2
   Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140. doi:10.1093/bioinformatics/btp61619910308
   PubMed Web of Science ®Google Scholar
• Carvajalrodríguez A, Uñaalvarez JD, Rolánalvarez E. A new multitest correction (SGoF) that increases its statistical power when increasing the number of tests. BMC Bioinformatics. 2009;10(1):209. doi:10.1186/1471-2105-10-20919586526
   PubMedGoogle Scholar
• Szekely GJ, Rizzo ML. Hierarchical clustering via joint between-within distances: extending ward‘s minimum variance method. J Classification. 2005;22(2):151–183. doi:10.1007/s00357-005-0012-9
   Web of Science ®Google Scholar
• Deza MM, Deza E. Encyclopedia of Distances‘. Ref Rev. 2009;24(6):1–583.
   Google Scholar
• Wang, L., Cao, C., Ma, Q., et al. RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14(1):169. doi:10.1186/s12870-014-0243-124939556
   PubMedGoogle Scholar
• Cheng D-D, Zhu B, Li S-J, Yuan T, Yang Q-C, Fan C-Y. Down-regulation of RPS9 inhibits osteosarcoma cell growth through inactivation of MAPK signaling pathway. J Cancer. 2017;8(14):2720. doi:10.7150/jca.1913028928861
   PubMed Web of Science ®Google Scholar
• Zhang, X., Ibrahimi, OA., Olesen SK., et al. Receptor specificity of the fibroblast growth factor family the complete mammalian fgf family. J Biol Chem. 2006;281(23):15694–15700. doi:10.1074/jbc.M60125220016597617
   PubMed Web of Science ®Google Scholar
• Kornmann, M., Ishiwata, T., Beger, HG., et al. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene. 1997;15(12):1417. doi:10.1038/sj.onc.12013519333017
   PubMed Web of Science ®Google Scholar
• Kornmann M, Lopez ME, Beger HG, Korc M. Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells. Int J Pancreatol. 2001;29(2):85–92. doi:10.1385/IJGC:29:2:08511876253
   PubMedGoogle Scholar
• Hanada K-I, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001;61(14):5511–5516.11454700
   PubMed Web of Science ®Google Scholar
• Douglas H, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Avruch J. MAP kinase pathways: the first twenty years. Biochimica Et Biophysica Acta (Bba)-Mol Cell Res. 2007;1773(8):1150–1160. doi:10.1016/j.bbamcr.2006.11.006
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37. doi:10.1038/3506500011242034
   PubMed Web of Science ®Google Scholar
• Ghavami S, Chitayat S, Hashemi M, et al. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 2009;625(1–3):73–83. doi:10.1016/j.ejphar.2009.08.04419835859
   PubMed Web of Science ®Google Scholar
• Cheng S, Zhang X, Huang N, Qiu Q, Jin Y, Jiang D. Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways. BMC Cancer. 2016;16(1):253. doi:10.1186/s12885-016-2294-127020242
   PubMedGoogle Scholar